Azithromycin News and Research

RSS
Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Treatment with chloroquine or hydroxychloroquine offers no benefit for COVID-19 patients

Treatment with chloroquine or hydroxychloroquine offers no benefit for COVID-19 patients

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

Modified clinical trial design to meet urgent community needs during COVID-19 pandemic

Modified clinical trial design to meet urgent community needs during COVID-19 pandemic

NIH begins clinical study to evaluate hydroxychloroquine and azithromycin for COVID-19

NIH begins clinical study to evaluate hydroxychloroquine and azithromycin for COVID-19

ACTG initiates clinical trial to evaluate treatment for COVID-19

ACTG initiates clinical trial to evaluate treatment for COVID-19

A 'multi-omics' approach to the development of drugs against COVID-19

A 'multi-omics' approach to the development of drugs against COVID-19

Clinical trial launched to evaluate experimental COVID-19 therapies

Clinical trial launched to evaluate experimental COVID-19 therapies

Perspective: Existing drugs could be repurposed for COVID-19 patients

Perspective: Existing drugs could be repurposed for COVID-19 patients

Combination therapy trial to understand the biology, spread, treatment of COVID-19

Combination therapy trial to understand the biology, spread, treatment of COVID-19

Hydroxychloroquine shown to slow recovery for COVID-19 patients

Hydroxychloroquine shown to slow recovery for COVID-19 patients

Hydroxychloroquine combined with azithromycin and abnormal heart rhythms in COVID-19 patients

Hydroxychloroquine combined with azithromycin and abnormal heart rhythms in COVID-19 patients

Anti-malarial drug use for COVID-19 associated with increased risk of cardiac arrhythmias

Anti-malarial drug use for COVID-19 associated with increased risk of cardiac arrhythmias

Online searches for unproven therapies for COVID-19

Online searches for unproven therapies for COVID-19

UTHealth experts successfully treat 3-week-old infant with severe COVID-19

UTHealth experts successfully treat 3-week-old infant with severe COVID-19

COVID-19 can trigger serious inflammatory-related cardiovascular problems

COVID-19 can trigger serious inflammatory-related cardiovascular problems

Early Heparin therapy improves hypoxia in COVID-19 patients

Early Heparin therapy improves hypoxia in COVID-19 patients

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

Is hydroxychloroquine effective against COVID-19?

Is hydroxychloroquine effective against COVID-19?

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes